Boehringer Purchases Nerio Therapeutics

In a $1.3 billion agreement, Boehringer Ingelheim purchased Nerio Therapeutics, a medication research and development business.

With Nerio’s novel PTPN2/N1 inhibitors, which have demonstrated encouraging anti-tumor efficacy, the purchase strengthens Boehringer’s immuno-oncology pipeline.

Phosphatases represent a difficult class of therapeutic protein targets that Nerio is concentrating on. The business has created PTPN2/N1 inhibitors that are extremely selective and have characteristics of drugs.

The purpose of the PTPN2/N1 inhibitors is to improve immune response and make tumours more susceptible to pro-inflammatory cues. By encouraging an anti-tumor reaction, this mechanism presents the inhibitors as possible advances in the treatment of cancer.

Boehringer Ingelheim managing directors board member Paola Casarosa stated: “Securing the rights to Nerio Therapeutics’ novel checkpoint inhibitors creates a broad panel of exciting new cancer treatment combination opportunities.’’

They continued: “This brings us a major step closer to our vision of transforming the lives of people living with cancer.”